WIKIMEDIA, NIAIDCRISPR pioneer Feng Zhang and his colleagues at MIT and elsewhere have identified a Cas9 enzyme, saCas9, which they used to successfully apply CRISPR gene-editing in living mice using an adeno-associated virus (AAV) vector. The team’s results were published in Nature this week (April 1).
“The paper illustrates that there is more to the Cas9 world than the first characterized protein (nuclease), and that new avenues will open as the toolbox is expanded,” Rodolphe Barrangou of North Carolina State University who was not involved in the study wrote in an e-mail.
“What’s exciting about [saCas9] is it works really well in vivo,” said Charlie Gersbach of Duke University who also did not participate in the work.
WIKIMEDIA, ASZAKALResearchers at the Washington University School of Medicine in St. Louis and their colleagues have developed personalized cancer vaccines, which they tested on three melanoma patients in order to assess immunologic effects. Their results were published in Science this week (April 2).
“Scientifically and immunologically, this was a tour de force as the first example of a personalized vaccine strategy,” said Jeffrey Weber, a tumor immunologist at the Moffitt Cancer Center ...
